

Medical writing – the inside story

Jenny Fanstone


Fanstone Medical Communications Ltd.

- ▶ Thomson Gardiner-Caldwell US
- ▶ Caudex Medical
- ▶ Communigen

AGENCY LIFE

- Publications
- Meetings
- Marketing materials
- Internal documents
- Websites
- [Regulatory]

WHAT WE DO



HOW WE DO IT



CODE OF PRACTICE for the PHARMACEUTICAL INDUSTRY



Home **CONSORT 2010** Extensions Downloads Examples Resources About CONSORT

CONSORT Checklist CONSORT Flow Diagram Translations Translation Policy

CONSORT 2010

The CONSORT (CONsolidated Standards of Reporting Trials) 2010 guideline is intended to improve the reporting controlled trial (RCT), enabling readers to understand a trial's design, conduct, analysis and interpretation, and to can only be achieved through complete adherence and transparency by authors.

CONSORT 2010 was developed through collaboration and consensus between clinical trial methodologists, guideline translation specialists, and journal editors (see [CONSORT group](#)). CONSORT 2010 is the current version of the guideline and 1996 versions. It contains a 25-item [checklist](#) and [flow diagram](#), freely available for viewing and [downloading](#)

[Extensions of the CONSORT Statement](#) have been developed for different types of trial designs, different interventions, and

The most important documents for understanding the CONSORT 2010 statement are the following:

1. **The CONSORT 2010 Statement:** This is a declaration of the standard, and how it was developed. This declaration or "statement" has been published in many prominent journals, including the British Medical Journal, the Lancet and PLoS Medicine. You can download the 2010 Statement documents [here](#).

REPORTING GUIDELINES

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies

Erik von Elm, MD; Douglas G. Altman, DSc; Matthias Egger, MD; Stuart J. Pocock, PhD; Peter C. Gøtzsche, MD; and Jan P. Vandenbroucke, MD, for the STROBE Initiative

Much of research strength should observational research to cover sections 2004, with the

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher, PhD; Alessandro Liberati, MD, DrPH; Jennifer Tetzlaff, BSc; Douglas G. Altman, DSc; and the PRISMA Group*

Editor's Note: In order to encourage dissemination of the PRISMA Statement, this article is freely accessible on the Annals of Internal Medicine Web site ([www.annals.org](#)) and will be also published in PLOS Medicine, BMJ, Journal of Clinical Epidemiology, and Open Medicine. The authors

article, we summarize a revision of these guidelines, re-named PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses), which have been updated to address several conceptual and practical advances in the science of systematic reviews (Box 1).

join use, S the of tice revi (3),

RESEARCH METHODS & REPORTING

Good publication practice for communicating company sponsored medical research: the GPP2 guidelines

Chris Graf,¹ Wendy P Battisti,² Dan Bridges,³ Victoria Bruce-Winkler,⁴ Joanne M Conaty,⁵ John M Ellison,⁶ Elizabeth A Field,⁷ James A Gurr,⁸ Mary-Ellen Marx,⁹ Mina Patel,¹⁰ Carol Sanes-Miller,⁵ Yvonne E Yarker,¹¹ for the International Society for Medical Publication Professionals

In response to changes in the environment in which authors, presenters, and other contributors work together to communicate medical research the **International Society for Medical Publication Professionals** has updated the good publication practice guidelines





IT CAN BE ABOUT
FAR-FLUNG PLACES...



...BUT YOU DON'T
REALLY SEE THEM

AND IT'S NOT
JUST ABOUT THE
WRITING





BUT ON BALANCE, IT'S NOT A
BAD CAREER ;)

Fanstone Medical Communications

Communicating your world

- ▶ jenny@fanstone.co.uk
- ▶ 0788 775 7503
- ▶ www.fanstonemedcomms.co.uk

JENNY FANSTONE
FANSTONE MEDICAL COMMUNICATIONS LTD.

